No abstract

No abstract

On the basis of experimental results by the Borstel Research Institute, 62 patients (BL and LL cases) from the Bisidimo-Center, Ethiopia, received a combination of rifampicin and Isoprodian for a definite length of time under control and clinicai conditions. In the same way 18 patients under dapsone monotherapy could be observed.During treatment good improvement could be seen under both medications, however, the improvement was better under the combined therapy. Side-effects were exceptional; reactions occurred in both grou ps.After therapy had to be discontinued, regular controls of the patients were arranged. In the dapsone group a deterioration was soon found, and treatment had to be continued; After combined therapy, however, the trend of improvement continued, the clinicai and bacteriological improvement has shown to be progres sive ; up to now (in many cases more than 2 years after treatment was stopped) no persistent signs of relapse could be found. The patients will continue under further observation.

No abstract